General Pharmacology Practice Questions

Q: Loading dose of a drug primarily depends on which pharmacokinetic parameter?

Volume of distribution. **Explanation:** The **Loading Dose (LD)** is a large initial dose given to achieve the **target plasma concentration ($C_p$)** rapidly. It is primarily determined by the **Volume of Distribution ($V_d$)**. The mathematical relationship is: $$\text{Loading Dose} = V_d \times \text{Target } C_p$$ Since the goal of a loading dose is to "fill up" the body's various compartments (tissues and plasma) to reach a steady state immediately, the drug's distribution characteristics ($V_d$) are the most critical factor. **Analysis of Options:** * **B. Clearance (CL):** This determines the **Maintenance Dose (MD)**, which is the dose required to replace the drug being eliminated to maintain a steady state. * **C. Rate of Administration:** While important for safety (to avoid toxicity from rapid IV push), it does not determine the calculated dose required to reach a target concentration. * **D. Half-life ($t_{1/2}$):** This determines the **time taken** to reach steady state (usually 4–5 half-lives) without a loading dose, but it does not dictate the size of the loading dose itself. **High-Yield Clinical Pearls for NEET-PG:** 1. **Loading Dose** = Rapidly reaches therapeutic levels; **Maintenance Dose** = Maintains steady state. 2. **Renal/Hepatic Failure:** In these conditions, clearance is reduced, so the **Maintenance Dose must be decreased**. However, the **Loading Dose remains the same** (unless the $V_d$ is significantly altered). 3. **Digoxin and Amiodarone:** These are classic examples of drugs requiring loading doses due to their large $V_d$ and long half-lives. 4. **Bioavailability (F):** If a drug is given orally, the formula becomes: $LD = (V_d \times \text{Target } C_p) / F$.

Q: Which of the following drugs can be administered subdermally?

Progesterone. **Explanation:** The correct answer is **Progesterone**. **1. Why Progesterone is correct:** Subdermal administration involves the surgical implantation of a drug-containing capsule or pellet under the skin (usually the upper arm). This route is designed for **long-term, sustained release** of drugs over months or years. Progesterone (and its analogs like Etonogestrel) is highly lipid-soluble and effective in minute quantities, making it ideal for subdermal implants (e.g., **Nexplanon**). These implants provide effective contraception for up to 3 years by bypassing first-pass metabolism and ensuring steady plasma concentrations. **2. Why the other options are incorrect:** * **Nicotine, Fentanyl, and Glyceryl trinitrate (GTN):** These drugs are typically administered via the **Transdermal (Patch)** route, not subdermal. * **Transdermal route:** Drug is applied to the surface of intact skin and absorbed into the systemic circulation through the dermis. It is non-invasive. * **Subdermal route:** Requires a minor surgical incision for implantation. **3. High-Yield Clinical Pearls for NEET-PG:** * **Subdermal Implants:** Common examples include **Norplant** (Levonorgestrel) and **Nexplanon**. * **Pellet Implantation:** Another form of subdermal delivery used for Testosterone and Estradiol. * **Transdermal Patches:** Preferred for drugs with high first-pass metabolism and short half-lives. Common examples: **Scopolamine** (motion sickness), **Nitroglycerin** (angina), **Fentanyl** (chronic pain), and **Nicotine** (smoking cessation). * **Key Advantage:** Both routes bypass the "First-pass effect," increasing bioavailability.

Q: An investigator is studying a potential new antiarrhythmic. Eighty healthy test subjects are receiving various doses of the drug. Adverse effects and the drug’s pharmacokinetics are assessed. Which of the following steps in the drug development process does this represent?

Phase I. ### Explanation **Correct Answer: B. Phase I** The scenario describes **Phase I clinical trials**, which are the first stage of testing a new drug in humans [1]. The primary goal of Phase I is to assess **safety, tolerability, and pharmacokinetics** (ADME: Absorption, Distribution, Metabolism, and Excretion) [3]. **Why Phase I is correct:** * **Subjects:** It typically involves a small group (**20–100**) of **healthy volunteers** [3] (except for highly toxic drugs like anti-cancer agents, where patients are used). * **Objective:** To determine the maximum tolerated dose and identify common side effects [3]. The mention of "80 healthy test subjects" and "pharmacokinetics" are classic indicators of Phase I. **Why other options are incorrect:** * **Phase II:** Focuses on **efficacy** ("proof of concept") [1] and optimal dosing in a small group of **patients** (100–300) who actually have the disease. * **Phase III:** Involves large-scale, multicenter, randomized controlled trials (RCTs) in **thousands of patients** to confirm efficacy and monitor for rarer adverse effects compared to existing treatments. * **New Drug Application (NDA):** This is the formal proposal submitted to regulatory authorities (like the FDA or DCGI) *after* Phase III is successfully completed [1] to gain marketing approval. --- ### High-Yield Clinical Pearls for NEET-PG * **Phase 0 (Microdosing):** Uses sub-therapeutic doses in <15 humans to study pharmacokinetics; it precedes Phase I. * **Phase IV (Post-marketing Surveillance):** Occurs after the drug is on the market to detect rare or long-term adverse effects (e.g., Phocomelia with Thalidomide) [2]. * **Trick for Subjects:** * Phase I = **H**ealthy volunteers (**H**ow safe?) * Phase II = **P**atients (**P**roof of concept) * Phase III = **L**arge scale (**L**egality/Approval) * **Success Rate:** Phase I has the highest success rate (~70%), while Phase II has the highest failure rate due to lack of efficacy [1].

Q: Which teratogen is known to cause deafness?

Isotretinoin. **Explanation:** **Isotretinoin (Option A)** is a highly potent teratogen used for severe acne. It causes a specific pattern of malformations known as **Retinoic Acid Embryopathy**. This occurs due to its interference with neural crest cell migration. Key features include **craniofacial abnormalities**, **microtia/anotia** (small or absent ears), and **congenital deafness** (sensorineural hearing loss). It also causes CNS defects and cardiovascular malformations (e.g., Transposition of Great Arteries). **Why other options are incorrect:** * **Chloroquine (Option B):** While it can cross the placenta, it is generally considered safe in pregnancy for malaria prophylaxis. High doses have been historically linked to eighth nerve damage, but it is not the classic association for deafness compared to Isotretinoin or Aminoglycosides. * **Alcohol (Option C):** Causes **Fetal Alcohol Syndrome (FAS)**, characterized by maxillary hypoplasia, smooth philtrum, thin upper lip, microcephaly, and mental retardation, but not typically primary deafness. * **Warfarin (Option D):** Causes **Fetal Warfarin Syndrome**, characterized by **nasal hypoplasia**, depressed nasal bridge, and stippled epiphyses (chondrodysplasia punctata). **High-Yield Clinical Pearls for NEET-PG:** * **Isotretinoin Rule:** Female patients must follow the **iPLEDGE program**, requiring two forms of contraception and a negative pregnancy test before starting therapy. * **Thalidomide:** Causes Phocomelia (seal-like limbs). * **Valproate:** Highest risk for Neural Tube Defects (Meningomyelocele). * **Phenytoin:** Fetal Hydantoin Syndrome (hypoplastic nails and phalanges). * **Aminoglycosides (e.g., Streptomycin):** Another major cause of ototoxicity/deafness in utero.

Q: Which one of the following drugs does not have an active metabolite?

Lisinopril. **Explanation:** The correct answer is **Lisinopril**. The underlying concept involves understanding **Prodrugs** and **Active Metabolites**. Most ACE inhibitors (like Enalapril or Ramipril) are prodrugs that require hepatic conversion into their active "-at" forms (e.g., Enalaprilat). However, **Lisinopril and Captopril** are the two notable exceptions; they are active drugs themselves and do not undergo metabolism to form active metabolites. Lisinopril is excreted unchanged in the urine. **Analysis of Incorrect Options:** * **Diazepam:** A classic example of a drug with multiple long-lived active metabolites, including **Desmethyldiazepam (Nordiazepam)**, Temazepam, and Oxazepam. This contributes to its prolonged duration of action. * **Propranolol:** It undergoes extensive first-pass metabolism to form **4-hydroxypropranolol**, which possesses beta-blocking activity similar to the parent compound. * **Allopurinol:** It is rapidly metabolized by xanthine oxidase to **Alloxanthine (Oxypurinol)**. Alloxanthine is a potent, non-competitive inhibitor of xanthine oxidase and is responsible for the majority of the drug's long-term clinical effect. **NEET-PG High-Yield Pearls:** * **ACE Inhibitor Exceptions:** Remember the mnemonic **"CL"** (Captopril and Lisinopril) as the ACE inhibitors that are **NOT** prodrugs. * **Lisinopril** is preferred in patients with liver disease because it does not require hepatic activation. * **Active Metabolite of Spironolactone:** Canrenone. * **Active Metabolite of Morphine:** Morphine-6-glucuronide (more potent than morphine). * **Prodrug of Epinephrine:** Dipivefrine (used in glaucoma).

Q: Idiosyncrasy is known to have which of the following components?

Genetic component. ### Explanation **1. Why Option A is Correct:** **Idiosyncrasy** (or Type B adverse drug reaction) refers to a genetically determined abnormal reactivity to a chemical or drug. Unlike standard side effects, these reactions are **unpredictable**, do not occur in most patients, and are not dose-dependent. The underlying mechanism is typically a **genetic polymorphism** involving drug-metabolizing enzymes or receptors. For example, a patient with a G6PD deficiency (a genetic trait) will experience hemolysis when given Primaquine; this is a classic idiosyncratic reaction. **2. Why Other Options are Incorrect:** * **B. Psychological component:** This refers to the **Placebo effect** (positive response) or **Nocebo effect** (negative response) based on the patient's expectations, rather than a biological reaction to the drug molecule itself. * **C. Physiological component:** Physiological factors include age, sex, or pregnancy, which influence drug pharmacokinetics (e.g., slower metabolism in neonates) but do not define the unique, "bizarre" nature of idiosyncrasy. * **D. Nutritional component:** While malnutrition can affect protein binding or liver function, it does not account for the specific, genetically-coded abnormal responses characteristic of idiosyncrasy. **3. NEET-PG High-Yield Pearls:** * **Type B Reactions:** Remember the mnemonic **"B" for Bizarre.** Idiosyncratic reactions are Type B (unpredictable, non-dose-related, high morbidity/mortality). * **Classic Examples:** * **Succinylcholine apnea:** Due to a genetic deficiency of pseudocholinesterase. * **Malignant Hyperthermia:** Triggered by Halothane/Succinylcholine due to a mutation in the *RYR1* (Ryanodine) receptor. * **Aplastic Anemia:** Caused by Chloramphenicol (idiosyncratic in most cases). * **Distinction:** Unlike allergies, idiosyncratic reactions do not require prior sensitization (no IgE involvement).

Q: Steady state concentration is typically achieved in how many half-lives?

5. **Explanation:** The concept of **Steady State Concentration ($C_{ss}$)** refers to the point during a drug’s administration where the rate of drug elimination equals the rate of drug administration. In first-order kinetics, this is a time-dependent process determined solely by the drug’s half-life ($t_{1/2}$). **Why Option C is Correct:** Mathematically, a drug reaches a specific percentage of its final steady-state concentration with each passing half-life: * 1 $t_{1/2}$: 50% * 2 $t_{1/2}$: 75% * 3 $t_{1/2}$: 87.5% * 4 $t_{1/2}$: 93.75% * **5 $t_{1/2}$: 96.875%** In clinical pharmacology, reaching **>95%** of the steady state is considered functionally complete. Therefore, it takes approximately **4 to 5 half-lives** to reach steady state. Since "5" is the standard benchmark in most textbooks (like Katzung and K.D. Tripathi) for achieving a stable therapeutic level, it is the preferred answer. **Why Other Options are Incorrect:** * **Option A (3 $t_{1/2}$):** Only 87.5% of the drug is accumulated; the plasma concentration is still rising significantly. * **Option B (4 $t_{1/2}$):** While 93.75% is close, 5 half-lives ensure the concentration is more stable and closer to the ultimate plateau. * **Option D (6 $t_{1/2}$):** While the drug is certainly at steady state by 6 half-lives, it is not the *earliest* point at which steady state is typically defined. **High-Yield NEET-PG Pearls:** 1. **Loading Dose:** To achieve therapeutic levels immediately without waiting for 5 half-lives, a loading dose is administered. 2. **Washout Period:** Similarly, it takes **5 half-lives** for a drug to be completely eliminated (97% cleared) from the body after stopping administration. 3. **Independence:** The time to reach steady state is **independent of the dose**; increasing the dose will increase the final concentration level but will not change the time (number of half-lives) taken to get there.

Q: Which of the following is the exact mechanism of action of Nitric Oxide (NO)?

Increase in cyclic guanosine monophosphate (cGMP). **Explanation:** Nitric Oxide (NO), also known as Endothelium-Derived Relaxing Factor (EDRF), is a potent endogenous vasodilator. Its mechanism of action is a high-yield topic for NEET-PG: 1. **Mechanism of the Correct Answer (B):** Nitric Oxide is a gas that diffuses across cell membranes into vascular smooth muscle cells. Once inside, it binds to and activates the enzyme **soluble Guanylyl Cyclase (sGC)**. This enzyme catalyzes the conversion of Guanosine Triphosphate (GTP) to **cyclic Guanosine Monophosphate (cGMP)**. Increased levels of cGMP activate Protein Kinase G (PKG), which leads to dephosphorylation of myosin light chains and sequestration of intracellular calcium, resulting in smooth muscle relaxation and vasodilation. 2. **Why Incorrect Options are Wrong:** * **Option A:** cAMP is the second messenger for drugs like Beta-2 agonists (Salbutamol) and Prostacyclin ($PGI_2$). While it also causes vasodilation, it is not the pathway for NO. * **Options C & D:** Prostaglandins ($PGE_2$ and $PGD_2$) are lipid mediators derived from arachidonic acid via the cyclooxygenase pathway. While they are involved in inflammation and vasodilation, they are not the mediators of NO action. (Note: $PGD_4$ is not a standard physiological prostaglandin). **Clinical Pearls for NEET-PG:** * **Nitrates (Nitroglycerin):** Act as prodrugs that are metabolized to release NO. * **Sildenafil (Viagra):** Inhibits Phosphodiesterase-5 (PDE-5), the enzyme that breaks down cGMP, thereby prolonging the effects of NO. * **Inhaled NO:** Used clinically in the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN). * **Precursor:** L-arginine is the amino acid precursor for NO synthesis via the enzyme Nitric Oxide Synthase (NOS).

Q: All of the following are true regarding Phase II clinical trials, except:

They are conducted in patients with the target disease.. **Explanation:** The correct answer is **B** because the statement "They are conducted in patients with the target disease" is actually a **true** characteristic of Phase II trials. In the context of an "except" question, the provided key suggests a potential error in the question's framing or the options provided, as Option D is the most scientifically inaccurate statement. **1. Why Option D is the correct "Except" (The False Statement):** Phase I trials are primarily designed to assess **safety, tolerability, and pharmacokinetics** in healthy volunteers. They are **not** designed to establish efficacy. Therefore, "positive evidence of efficacy" cannot be a prerequisite from Phase I, as efficacy is first explored in Phase II. **2. Analysis of Other Options:** * **Option A (True):** Phase II is the first time the drug is tested for **efficacy** (does it work?) while continuing to monitor **safety** in a larger group than Phase I. * **Option B (True):** Unlike Phase I (healthy volunteers), Phase II trials are conducted in a small group (100–300) of **patients** who actually have the target disease. * **Option C (True):** Phase II trials are officially designated as **Therapeutic Exploratory** trials because they aim to determine the therapeutic dose range and initial clinical effect. **High-Yield Clinical Pearls for NEET-PG:** * **Phase I:** Safety & Pharmacokinetics (Healthy volunteers; "Human Pharmacology"). * **Phase II:** Efficacy & Dose-ranging (Small patient group; "Therapeutic Exploratory"). * **Phase III:** Confirmation of efficacy & safety (Large multicentric patient group; "Therapeutic Confirmatory"). * **Phase IV:** Post-marketing surveillance (Detects rare/long-term adverse effects). * **Phase 0:** Microdosing trials to study pharmacokinetics (Sub-therapeutic doses).

Question 1

Loading dose of a drug primarily depends on which pharmacokinetic parameter?

Accepted Answer

Volume of distribution

Answer

Clearance

Answer

Rate of administration

Answer

Half-life

Question 2

Which of the following drugs can be administered subdermally?

Accepted Answer

Progesterone

Answer

Nicotine

Answer

Fentanyl

Answer

Glyceryl trinitrate (GTN)

Question 3

Which schedule of drug is to be sold only on prescription?

Accepted Answer

H

Answer

P

Answer

G

Answer

X

Question 4

An investigator is studying a potential new antiarrhythmic. Eighty healthy test subjects are receiving various doses of the drug. Adverse effects and the drug’s pharmacokinetics are assessed. Which of the following steps in the drug development process does this represent?

Accepted Answer

Phase I

Answer

New drug application (NDA)

Answer

Phase II

Answer

Phase III

Question 5

Which teratogen is known to cause deafness?

Accepted Answer

Isotretinoin

Answer

Chloroquine

Answer

Alcohol

Answer

Warfarin

Question 6

Which one of the following drugs does not have an active metabolite?

Accepted Answer

Lisinopril

Answer

Diazepam

Answer

Propanolol

Answer

Allopurinol

Question 7

Idiosyncrasy is known to have which of the following components?

Accepted Answer

Genetic component

Answer

Psychological component

Answer

Physiological component

Answer

Nutritional component

Question 8

Steady state concentration is typically achieved in how many half-lives?

Accepted Answer

5

Answer

3

Answer

4

Answer

6

Question 9

Which of the following is the exact mechanism of action of Nitric Oxide (NO)?

Accepted Answer

Increase in cyclic guanosine monophosphate (cGMP)

Answer

Increase in cyclic adenosine monophosphate (cAMP)

Answer

Increase in prostaglandin E2 (PGE2)

Answer

Increase in prostaglandin D4 (PGD4)

Question 10

All of the following are true regarding Phase II clinical trials, except:

Accepted Answer

They are conducted in patients with the target disease.

Answer

They assess safety and efficacy.

Answer

They are considered therapeutic exploratory trials.

Answer

Positive evidence of efficacy from Phase I trials is a prerequisite.

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?